Company profile: Oncoscope
1.1 - Company Overview
Company description
- Provider of optical biopsy and imaging systems for epithelial tissues in the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder, delivering in vivo measurements of cell nuclei diameter and density to help physicians identify pre-cancerous tissues for biopsy.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oncoscope
Immune-Onc Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune-Onc Therapeutics company profile →
RainDance Technologies
HQ: United States
Website
- Description: Provider of medical technology solutions leveraging droplet technology for research in areas including non-invasive liquid biopsy, and offering molecules, single-cell analyses, reaction methodology, cancer research, mutation detection, and diagnostics services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RainDance Technologies company profile →
Ventana
HQ: United States
Website
- Description: Provider of tissue-based diagnostic solutions, medical diagnostic systems, and biopsy-based cancer tests. Offers pathology lab instruments, cytology and tissue-based assays, and software for anatomic pathology labs; point-of-care coagulation monitoring; in-vitro diagnostics for clinical chemistry, immunochemistry, PCR, and mass spectrometry; biotech raw materials and QC kits; and non-invasive prenatal screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ventana company profile →
OncoEthix
HQ: Switzerland
Website
- Description: Provider of cancer drug development, advancing a portfolio of three to five promising oncology compounds through clinical development; a private Swiss company founded in 2007.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoEthix company profile →
Immunomic Therapeutics
HQ: United States
Website
- Description: Provider of lysosomal associated membrane protein-based immunotherapies and vaccines via its UNITE platform, leveraging natural biochemistry to elicit broad immune responses. Pipeline includes ITI-1000 (autologous dendritic cell therapy for glioblastoma), ITI-1001 (off-the-shelf CMV-targeting GBM immunotherapy), ITI-3000 (plasmid DNA vaccine for Merkel cell carcinoma), ITI-1771 (for CMV-driven cancers), and ITI-5000 (saRNA vaccine for TNBC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunomic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oncoscope
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oncoscope
2.2 - Growth funds investing in similar companies to Oncoscope
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oncoscope
4.2 - Public trading comparable groups for Oncoscope
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →